Background/aims: : The mucoprotective drug rebamipide is used to treat gastritis and peptic ulcers. We compared the efficacy of Mucosta (rebamipide 100 mg) and its new formulation, AD-203 (rebamipide 150 mg), in treating erosive gastritis.
Methods: This double-blind, active control, noninferiority, multicenter, phase 3 clinical trial randomly assigned 475 patients with endoscopically proven erosive gastritis to two groups: AD-203 twice daily or Mucosta thrice daily for 2 weeks. The intention-to-treat (ITT) analysis included 454 patients (AD-203, n=229; Mucosta, n=225), and the per-protocol (PP) analysis included 439 patients (AD-203, n=224; Mucosta, n=215). The posttreatment assessments included the primary (erosion improvement rate) and secondary endpoints (erosion and edema cure rates; improvement rates of redness, hemorrhage, and gastrointestinal symptoms). Drug-related adverse events were evaluated.
Results: According to the ITT analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta-treated patients were 39.7% and 43.8%, respectively. According to the PP analysis, the erosion improvement rates (posttreatment) in AD-203-treated and Mucosta-treated patients were 39.3% and 43.7%, respectively. The one-sided 97.5% lower limit for the improvement rate difference between the study groups was -4.01% (95% confidence interval [CI], -13.09% to 5.06%) in the ITT analysis and -4.44% (95% CI, -13.65% to 4.78%) in the PP analysis. The groups did not significantly differ in the secondary endpoints in either analysis. Twenty-four AD-203-treated and 20 Mucosta-treated patients reported adverse events but no serious adverse drug reactions; both groups presented similar adverse event rates.
Conclusions: The new formulation of rebamipide 150 mg (AD-203) twice daily was not inferior to rebamipide 100 mg (Mucosta) thrice daily. Both formulations showed a similar efficacy in treating erosive gastritis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593495 | PMC |
| http://dx.doi.org/10.5009/gnl20338 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Megaoesophagus associated to inflammatory infiltrate in the autonomous plexus in a 7-year-old Spanish Water Dog.
BMC Vet Res
November 2024
Departamento de Anatomía y Anatomía Patológica Comparadas y Toxicología, UIC Zoonosis y Enfermedades Emergentes (ENZOEM), Universidad de Córdoba, Córdoba, Spain.
Background: Megaoesophagus (ME), a disorder of the oesophagus characterized by diffuse oesophageal dilation and decreased peristalsis that may be congenital or acquired. Knowledge regarding the aetiology and prognosis for canine acquired ME is currently limited with most cases being idiopathic, which is a considerable problem to implement an appropriate treatment and a potential better prognosis.
Case Presentation: A 7-year-old, neutered, female Spanish Water Dog was evaluated for progressive weight loss, chronic vomiting and regurgitation.
A Case of Olmesartan-associated Gastritis Observed Over Time.
Intern Med
November 2024
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Japan.
A 61-year-old woman who had been taking olmesartan for 7 years complained of epigastric pain, diarrhea, loss of appetite, and weight loss. Esophagogastroduodenoscopy revealed roughened mucosa and erosions in the stomach and duodenum. An endoscopic biopsy failed to identify the cause of the mucosal disorder.
View Article and Find Full Text PDFA Gastrointestinal Manifestation of Primary Cutaneous Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma: A Case Report.
Cureus
October 2024
Gastroenterology, Hackensack Meridian Health, Palisades Medical Center, North Bergen, USA.
Article Synopsis
- Cutaneous T-cell lymphomas (CTCL) are the most common type of primary skin lymphoma, primarily affecting the skin but also showing extracutaneous symptoms.
- Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphoma (pcAECTCL) is a rare, aggressive subtype with poor outcomes and potential for systemic spread, particularly to organs like the lungs and central nervous system.
- A case study is presented of a patient with a persistent rash diagnosed with pcAECTCL, where imaging showed possible gastric involvement, but no definitive evidence of metastasis was found after further examination.
Endoscopic and pathological features of neoplastic transformation of gastric hyperplastic polyps: Retrospective study of 4010 cases.
World J Gastrointest Oncol
November 2024
Department of Gastroenterology, Peking University Third Hospital, Beijing 100191, China.
Background: Hyperplastic polyps, which represent 30%-93% of all gastric epithelial polyps, are the second most common type of gastric polyps after fundic gland polyps. They were previously considered to have no risk of neoplastic transformation. Recently, an increasing number of cases of gastric hyperplastic polyps (GHPs) combined with neoplastic changes have been reported; however, the specific mechanism underlying their transformation has not been thoroughly explored.
View Article and Find Full Text PDFThe Irony of Iron Pill Gastritis: A Case of Delayed Recognition and Persistent Injury in an Elderly Patient.
Cureus
October 2024
Department of Gastroenterology, California Gastroenterology Associates, Fresno, USA.
Article Synopsis
- Iron pill gastritis is a rare but serious issue that can occur from oral iron supplements, especially in older adults.
- An 83-year-old man developed gastric ulcers after taking ferrous sulfate for iron deficiency anemia, and tests confirmed he had iron pill gastritis.
- This case emphasizes the need for doctors to recognize this condition early, educate patients about the risks, and consider using liquid iron instead of solid tablets for those at higher risk.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!